Drug Profile
Research programme: cell therapies - SQZ Biotech
Alternative Names: CellSqueeze; CellSqueeze platform; SQZ-APCsLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator SQZ Biotech
- Class Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Type 1 diabetes mellitus
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Type-1 diabetes mellitus in USA (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)